Sentences with phrase «ovarian response»

Researchers found that L - arginine, which is an amino acid can increase ovarian response, endometrial receptivity, and pregnancy rates in IVF patients who were perviously poor responders.

Nitric oxide helps increase circulation and has been shown to improve ovarian response.

Co-enzyme q10 supplementation improves ovarian response and mitochondrial function in aged mice [abstract].

While DCI has been shown to improve insulin and androgens in PCOS, Isabella et al in 2012 showed that DCI alone, administered at high dosages (600-2400 mg daily) has been found to negatively affect oocyte quality and ovarian response.

«While the reason for this association is difficult to explain, the potential factors could be the observed differences in cause of infertility, ovarian response, fertilisation rates and implantation rates, which are all independent predictors of IVF success.

At VCRM, there are few ongoing clinical trials to improve ART success, AM compared to PM gonadotropin dosing, and for prevention of ovarian hyperstimulation syndrome (OHSS), along with protocols to help improve ovarian response in poor responders (DOR).

Research has therefore shown that l - arginine supplementation can help to enhance endometrial receptivity, improve ovarian responses, and increase pregnancy rate in women undergoing IVF treatments10.

Not exact matches

Could advanced glycation end products explain the poor response to controlled ovarian hyperstimulation in obese women

It's important to understand that ovarian reserve testing is just a part of the picture, in combination with the patient's age and response to previous treatment.

«Personalized tumor vaccine shows promise in pilot trial: Vaccine against patients» own tumors triggers a broad response, and induced five - year remission in one patient with advanced ovarian cancer.»

Spontaneous immune responses were assessed by measuring serum antibodies against ovarian cancer - associated antigens, such as NY - ESO - 1, that are not expressed in normal body tissues but are expressed in cancers.

Doctors at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix reported today in Lancet Oncology that a new treatment for ovarian cancer can improve response rates (increase the rate of tumor shrinkage) and prolong the time until cancers recur.

Their results demonstrate that specific rhoptry and dense granule effector proteins that T. gondii secretes before and after host cell invasion, respectively, control the development of an effective host antitumor response, and increase the survival of mice with ovarian tumors.

The resulting «map» of gene - drug interactions allowed the researchers to accurately predict the responses of multiple human cancer cell lines to different chemotherapy agents based on the cell lines» genetic profiles and also revealed new genetic factors that appear to determine the response of breast and ovarian tumor cells to common classes of chemotherapy treatment.

ONLY half of women diagnosed with ovarian cancer live for five or more further years, but a «vaccine» that provokes an immune response against cancer might change that.

Our approach is to study more than one or two serial recurrences of the disease, adding information about the response to therapy and natural progress of ovarian cancer,» adds J. Brian Szender, MD, MS, senior author and a fellow in Gynecologic Oncology at RPCI.

Among 10 women with advanced ovarian cancer who got injections of the personalized vaccine once every three weeks — with the medications cyclophosphamide and bevacizumab (marketed as Avastin)-- eight showed a strong immune response and were still alive after two years.

[4] Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, Jungbluth AA, Ritter G, Aghajanian C, Bell - McGuinn K, Hensley ML, Konner J, Tew W, Spriggs DR, Hoffman EW, Venhaus R, Pan L, Salazar AM, Diefenbach CM, Old LJ, Gnjatic S. Phase I trial of overlapping long peptides from a tumor self - antigen and poly - ICLC shows rapid induction of integrated immune response in ovarian cancer patients.

First - line treatment for ovarian cancer includes surgery followed by a chemotherapy regimen combining a platinum - based (usually carboplatin) and a taxane - based (usually paclitaxel) treatment, which achieves a complete response in approximately 80 % of patients.

He previously revealed the existence of spontaneous immune responses in ovarian tumors as well as described how regulatory T cells and tumor blood vessels affect these responses.

The team plans to further analyze the microbiome to diagnosis ovarian and endometrial cancers and evaluate responses to treatment.

In that randomized, double - blind, placebo - controlled, phase III trial, 561 patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who were in complete or partial response to platinum - based chemotherapy were treated with either rucaparib 600 mg orally twice daily (372 patients) or to placebo (189 patients).

The women's immune systems — in mounting a response against the synaptic receptors present in the ovarian growths — inadvertently attacked a receptor in the brain called N - methyl - D - aspartate receptor, or NMDAR.

ZEJULA is the first and only once - daily PARP inhibitor for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum - based chemotherapy.1 - 3

ZEJULA is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum - based chemotherapy.

Over the past few years, they have extended their research to understand how products of cellular necrosis and the innate immune responses they induce affect the tumor microenvironment, with a specific focus on ovarian cancer.

A total of 265 women took part in the trial, all of whom had high - grade serous ovarian cancer and had recently completed a course of platinum - based chemotherapy which had achieved a complete or partial response.

These mechanisms have significant relevance in ovarian cancers and stress response, pathophysiological conditions in which miR - 200c / 141 exert key functions (Batista, Nature Communications, 2016).

Research appearing in Developmental Cell details the discovery of genes located in two genomic regions whose copy numbers are increased in response to differentiation of the ovarian follicle cells.

Alexandra Snyder, MD, is a translational physician scientist at Memorial Sloan Kettering Cancer Center (MSKCC) who specializes in the study of tumor genetics and response to checkpoint blockade immunotherapy in solid tumors, with a particular focus on ovarian cancer.

Although clinical trials have collectively shown a disease control rate of approximately 45 percent using this approach in ovarian cancer, they have yet to establish selective benefit in BRCA1 / 2 - deficient cancers, which should generate stronger anti-tumor immune responses given their higher mutation rate.

Odunsi K, Qian F, Matsuzaki J, Mhawech - Fauceglia P, Andrews C, Hoffman EW, Pan L. Ritter G, Villella J, Thomas B, Rodabaugh K, Lele S, Shrikant P, Old LJ, Gnjatic S. (2007) Vaccination with an NY - ESO - 1 peptide of HLA class I / II specificities induces integrated humoral and T cell responses in ovarian cancer.

Penn Study Finds Relationship between PTEN Loss, Potential for Immune Response in BRCA 1 / 2 - Deficient Ovarian Cancer

Several other drugs that are designed to modulate the anti-cancer immune response, such as anti-PD1 and anti-GITR, are showing promise in experimental studies in melanoma and other cancers, including colorectal, kidney, lung, prostate, and ovarian cancers and sarcoma.

In the experiments described in the paper, the MGH team confirmed that their mesothelin - targeting fusion protein binds to mesothelin on either ovarian cancer or mesothelioma cells, activates dendritic cells, and enhances the cells» processing and presentation of several different tumor antigens, inducing a number of T - cell - based immune responses.

After receiving overwhelming response for Polycystic Ovarian Syndrome Conference, OMICS International is glad to announce «2nd World Congress on Polycystic Ovarian Syndrome» going to held on October 05 - 07, 2016 in Orlando, FL..

In a study observing its effects on ovarian cancer cells and cell - mediated responses, Reishi inhibited cell colony formation and cell migration demonstrating its ability to protect already healthy cells.

For instance, elevated TPO antibodies, a marker for Hashimoto's, are associated with poor treatment response in infertile women who also suffer from polycystic ovarian syndrome (PCOS).

One study from UC Davis found walnuts to improve endocrine markers in women with polycystic ovarian syndrome (PCOS), improving cholesterol, insulin response (PCOS is commonly associated with insulin resistance) and sex hormone - binding globulin, which is responsible for the transport of hormones through the body.

Anticipated health behaviour changes and perceived control in response to disclosure of genetic risk of breast and ovarian cancer: a quantitative survey study among women in the UK